RM-GHA / Growth-hormone-axis signalling
CJC-1295 (no DAC)
Also known as: Modified GRF 1-29 · Mod-GRF(1-29)
Grade describes the published research on the molecule. It is not a quality score, a safety score, or a release state.
What this is
A modified GHRH analog. Critically, the widely cited human literature concerns the long-acting drug-affinity-complex (DAC) form, which is a different material.
Evidence position
Grade D. This is the clearest example in the catalog of why exact identity matters: a ‘no DAC’ material cannot inherit evidence generated for the DAC form. Exact sequence and modification are mandatory before any evidence is attached.
What the record does not establish
Published research about a molecule is not a test of any particular vial. Identity, purity, strength and microbiological quality are established by lot-level analytical records tied to a matched sample — not by the literature, and not by the presence of an approved comparator.
Where a lot-level record exists it is published on the evidence page and linked from the product. Where it does not exist, the record says so.
Sources
- 01CJC-1295 human study (DAC form)PubMed
- Shows
- Human data for the DAC form
- Does not show
- Does not apply to the no-DAC material
- 02Bulk drug substances that may present significant safety risksU.S. Food and Drug Administration
- Shows
- Regulator safety position
- Does not show
- Not a quality assessment of any vial
External database index
LIVE DATABASE INDEX / SEPARATE FROM CURATED EVIDENCE
Records below come directly from public scientific databases. They help find relevant material, but do not affect the evidence grade until they are matched to the molecule and added to the curated source list.
PUBMED / FOUND RECORDS
- Glycine-modified growth hormone secretagogues identified in seized doping material.Drug testing and analysis / 2019 FebPMID 30136411 / DOI 10.1002/dta.2489
- The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration.Frontiers in endocrinology / 2026PMID 42395176 / DOI 10.3389/fendo.2026.1822475